Helen Albert is a Senior Editor at various esteemed publications including Chemistry World, Inside Precision Medicine, and Labiotech.eu. She specializes in themes surrounding medicine and healthcare, with a keen focus on topics such as coronavirus, AI, FDA regulations, and social issues impacting the healthcare system. Helen's insightful work has been featured in notable outlets like BioPharma-Reporter, Genetic Engineering & Biotechnology News, NewsBreak, and Outsourcing-Pharma.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Helen's coverage is predominantly focused on healthcare and pharmaceuticals, with an emphasis on scientific breakthroughs. Her articles frequently cite data, indicating a preference for evidence-based reporting.
Given the technical and research-oriented nature of her articles, Helen would likely be interested in sources who can provide expert insights into cutting-edge medical research or technological advancements within the healthcare and pharmaceutical sectors.
Articles featuring biotech movies suggest she could also be open to human-interest pieces related to the industry. However, it's essential that pitches align with her focus on scientific and evidence-based content.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Helen Albert
Antimicrobial drugs have saved billions of lives over the last century, but during the last 30 years, deaths due to antimicrobial resistance (AMR) have increased exponentially. While there are many early-stage companies and researchers working to bring new treatments and diagnostics to market, success seems difficult due to reimbursement issues.
New research shows machine learning could help predict the onset of schizophrenia and bipolar disorder by analyzing routine clinical data from electronic health records.
A new rice variety that combines high yield with low methane emissions could help farmers tackle climate change.
Heart inflammation is caused by different cellular reactions, which could lead to the development of more targeted therapies.
Adding people of non-White ancestry to a study assessing the genetics of Alzheimer's led to the identification of 16 new areas of variation.
The monoclonal antibody omalizumab is a good treatment option for people with multiple food allergies who can't tolerate oral immunotherapy.
Treatment outcomes improve in people with multiple sclerosis (MS) by focusing on clinical and socioeconomic factors, but not ethnicity.
Older people with good cardiovascular health have lower levels of neurofilament light, a biomarker of neurodegenerative diseases.
PhyloFrame, a machine learning tool, can help improve the accuracy of genetic disease prediction tests in people of non-White ancestry.
By: Helen Albert
First PROTAC degrader drug to reach Phase III shows mixed results in breast cancer, with efficacy only in estrogen receptor 1-mutants.
(833) 317-6278 
